Pipeline

Pipeline targeting Respiratory Viruses

Bivalent RSV-hMPV candidate vaccine

The VXB-241 vaccine candidate targets respiratory syncytial virus (RSV) and human metapneumovirus (hMPV), a major cause of severe respiratory diseases in young children and older adults.

The VXB-241 candidate vaccine has shown to induce high levels of neutralising antibodies in preclinical.

The production yield of the candidate vaccine antigens are exceptional and the final VXB-241 final liquid formulation is stable at room temperature.

VXB-241 has been progressing into development activities with the objective to start a Phase 1 proof-of-concept clinical study during the second half of 2024.

The ambition is to deliver a bivalent RSV-hMPV vaccine with best-in-class efficacy as a ready-to-use fully liquid formulation.

Key references

Trivalent RSV-hMPV-PIV3 candidate vaccine

Human parainfluenza type 3 (PIV3) is recognised as an additional respiratory virus of concern causing significant burden of respiratory illness in young children and older adults.

Discovery and preclinical experiments are underway to deliver the PIV3 preF antigen capable of raising protective immunity.

In the future, Vicebio will apply the Molecular Clamp technology to develop multivalent formulations targeting several respiratory viruses into ready-to-use single shot vaccines.

Key references

Influenza candidate vaccine

When applied to influenza A strains, the Molecular Clamp technology has been shown to generate highly stable hemaglutinin antigen which is in “prefusion” conformation and is inducing a potent neutralisation response. Furthermore, upon challenge, vaccinated animals show broader protection than that induced by standard of care.

Additional work is ongoing to evaluate the performance of the technology with influenza B strains.

See McMillan et al : “Development of Molecular Clamp stabilised hemagglutinin vaccines for influenza A viruses”.

SARS-CoV-2 candidate vaccine

A previous version of the Molecular Clamp technology has been successfully used with the spike glycoprotein of the SARS-CoV-2 virus. In a clinical trial conducted in by The University of Queensland with funding from the Coalition for Epidemic Preparedness Innovations (CEPI), the spike antigen stabilised with the Molecular Clamp approach has been shown to induce high levels of neutralisating antibodies superior to convalescent sera both in young and elderly individuals. 

Vaccines targeting other viruses

The Molecular Clamp technology has also been applied to many other viruses including MERS, Ebola, Nipah, Lassa, HTLV-1, CMV and HSV viruses. Protective immunity has been demonstrated for Ebola, MERS, and Nipah in animal challenge models. The broad applicability of the technology in vaccinology is being further evaluated for other indications.